LEADS BIOLABS-B (09887) Announces Six Study Abstracts Published for ESMO 2026

Stock News10-19

LEADS BIOLABS-B (09887) has released an announcement that the complete abstracts of six studies—covering clinical research, translational research, and meta-analyses—for its independently developed Lixin® (opratuzumab, an anti-PD-L1/4-1BB bispecific antibody) and LBL-034 (a GPRC5D/CD3 bispecific T-cell engager, TCE) have been published on the official website of the 2026 European Society for Medical Oncology Annual Meeting (ESMO 2026).

The data collectively demonstrate Lixin®'s trend of durable responses and long-tail survival benefits across multiple immune "cold tumors," supporting its potential as a pan-tumor therapy and highlighting the differentiated capabilities of the company's X-body and TCE technology platforms.

Notably, three studies of Lixin® and LBL-034 were selected for preferred oral presentations at ESMO 2026, with one study selected as a Late-Breaking Abstract (LBA). Detailed and updated data from these studies will be released during the ESMO 2026 oral presentation sessions.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment